CSL Ltd.'s sales grew 15% in its last fiscal year and are expected to grow about 8% in FY 2018, but the Australia-based company is looking beyond its plasma protein expertise to outside innovation to help boost future revenue.
CSL Ltd. is not a typical biopharmaceutical company, given its plasma collection business and plasma-derived product expertise, but it has the same goal as many of its peers – to bring in more external innovation that augments the company's organic growth.
The Australian specialty pharma firm has an American CEO, Paul Perreault, who is based in Pennsylvania but spends most of...
Create an account to read this article
Already a subscriber?
Ultragenyx updated investors on interactions with the US FDA on gene therapy, while new drug launches were themes for Ionis and Organon in Q2 reporting.
CMO Shreeram Aradhye talks to Scrip about the promise shown by ianalumab, remibrutinib and a next-generation CAR-T for immunological disorders.
Aurobindo is confident its planned Lannett acquisition will pass US FTC scrutiny after an attempt to acquire Sandoz assets was called off in 2020 post a delay in approval. The deal could widen Aurobindo’s US manufacturing presence at a time when its US Q1 revenue saw a year-on-year decline
AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.
Shares of the Palo Alta, CA-based firm fell as Attruby sales missed elevated investor expectations in the second full quarter since its launch.
CMO Shreeram Aradhye talks to Scrip about the promise shown by ianalumab, remibrutinib and a next-generation CAR-T for immunological disorders.
CEO Robert Bradway expressed support on the company’s Q2 earnings call for lower drug prices but said it was “premature” to comment in detail on particular proposals.
